Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound sodium alginate double-layer chewable tablets for GERD
CTR20132947Phase 3Completed
- Sponsor
- Hebikang
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Gaviscon Double Action in gastroesophageal reflux disease (GERD), sponsored by Hebikang. Started May 2014; status: completed.
02
Drugs
Gaviscon Double Action
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on CTR20132947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132947.